NCT00328653View on ClinicalTrials.gov

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 22, 2007

Conditions
Conjunctivitis, Vernal
Interventions
DRUG

Cyclosporine NOVA22007 0.05%

DRUG

Cyclosporine NOVA22007 0.1%

DRUG

Vehicle

Trial Locations (1)

75018

Groupe Hospitalier Bichat-Claude Bernard, Paris

All Listed Sponsors
lead

Santen SAS

INDUSTRY

NCT00328653 - Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC) | Biotech Hunter | Biotech Hunter